PARD - TheStreet

Summary

Profile

Financials

Events

Ownership

Options

Company Info

Industry	n/a
Sector	n/a
Employees	n/a
CEO	n/a

Address	, ,
Phone	n/a
Website	n/a

Competitors

Company Name	3 Month %Change	1 Year %Change
No competitor information is available.

Statement Summary

as of 11:40 ET AM 09/24/2021

Total Assets (MRQ)	7.7 M
Total Liabilities (MRQ)	4.6 M
Shareholders’ Equity (MRQ)	n/a
Total Revenue (Annual)	n/a
Net Income (Annual)	-3.8 M

Earnings And Estimates

as of 11:40 ET AM 09/24/2021

Current Qtr EPS Estimate	n/a
Current FY EPS Estimate	n/a
Long Term EPS Growth Estimate	34.80
Next Expected Earnings Date	//

PARD vs S&P 500

as of 09/24/2021

	Relative To S&P 500	PARD
4 Weeks	n/a	n/a
12 Weeks	n/a	n/a
YTD	n/a	n/a

Earnings Surprises

as of 11:40 ET AM 09/24/2021

Fiscal Quarter	Estimate	Actual	Surprise
09/2011	-2.16	-2.40	+11.11%
06/2011	-2.20	-2.80	+27.27%
03/2011	-4.60	-2.40	-47.83%
12/2010	-5.00	-4.40	-12.00%
09/2010	-5.85	-5.20	-11.16%
06/2010	-7.86	-5.60	-28.75%
03/2010	-9.17	-11.60	+26.57%
12/2009	-11.60	-14.40	+24.14%

Financial Strength

as of 11:40 ET AM 09/24/2021

Pre-Tax Margin	0.00
Net Margin	0.00
Operating Margin	0.00
Return On Equity	-210.37
Return On Assets	-82.52
Inventory Turnover (TTM)	0.00
Sales Growth (MRQ)	n/a

Ratios

as of 11:40 AM ET 09/24/2021

Price/Earnings (TTM)	n/a
Price/Book (MRQ)	0.00
Price/Cash Flow (TTM)	0.00
Book Value (MRQ)	0.72
Quick Ratio (MRQ)	0.76
Current Ratio (MRQ)	0.76
Total Debt/Equity (MRQ)	0.53

Short Interest

as of 11:52 AM ET 09/27/2021

	% Short - 0.00%
	% Remaining Float - 100.00%

	Current	Last Month
Short Interest Date	n/a	n/a
Short Interest Shares	n/a	n/a
Short Interest Ratio	n/a	n/a

M Y M Y

Total Assets 0,0.00 0,0.00

Total Liabilities 0,0.00 0,0.00

Total Equity 0,0.00 0,0.00

M Y M Y

Total Revenue 0,0.00 0,0.00

EBT Exc.
Unusual Items 0,0.00 0,0.00

Net Income 0,0.00 0,0.00

M Y M Y

Cash from
Operations 0,0.00 0,0.00

Cash from
Activities 0,0.00 0,0.00

Cash from
Fin. Activities 0,0.00 0,0.00

Select Period

TOTAL ASSETS	TOTAL LIABILITIES	TOTAL EQUITY

Balance Sheet

	M Y
ASSETS
Cash And Equivalents	0,0.00
Receivables	0,0.00
Inventories	0,0.00
Other Current Assets	0,0.00
Total Current Assets	0,0.00
Property, Plant & Equipment, Gross	0,0.00
Accumulated Depreciation & Depletion	0,0.00
Property, Plant & Equipment, Net	0,0.00
Intangibles	0,0.00
Other Non-Current Assets	0,0.00
Total Non-Current Assets	0,0.00
TOTAL ASSETS	0,0.00
Liabilities & Shareholder Equity
Accounts Payable	0,0.00
Short Term Debt	0,0.00
Total Current Liabilities	0,0.00
Long Term Debt	0,0.00
Deferred Income Taxes	0,0.00
Other Non-Current Liabilities	0,0.00
Minority Interest	0,0.00
Total Non-Current Liabilities	0,0.00
Preferred Stock Equity	0,0.00
Common Stock Equity	0,0.00
Common Par	0,0.00
Additional Paid In Capital	0,0.00
Cumulative Translation Adjustment	0,0.00
Retained Earnings	0,0.00
Treasury Stock	0,0.00
Other Equity Adjustments	0,0.00
Total Capitalization	0,0.00
TOTAL EQUITY	0,0.00
TOTAL LIABILITIES & STOCK EQUITY	0,0.00
Total Common Shares Outstanding	0,0.00
Preferred Shares	0,0.00
Treasury Shares	0,0.00
Basic Weighted Shares Outstanding	0,0.00
Diluted Weighted Shares Outstanding	0,0.00
Number Of Employees	0,0.00
Number Of Part-Time Employees	0,0.00

Select Period

TOTAL REVENUES	EBT Excluding Unusual Items	NET INCOME

Income Statement

	M Y
Sales	0,0.00
Cost Of Sales	0,0.00
Gross Operating Profit	0,0.00
Selling, General, And Administrative Expenses	0,0.00
Research & Development	0,0.00
Operating Income Before D & A (EBITDA)	0,0.00
Depreciation & Amortization	0,0.00
Interest Income	0,0.00
Other Income - Net	0,0.00
Special Income / Charges	0,0.00
Total Income Before Interest Expenses (EBIT)	0,0.00
Interest Expense	0,0.00
Pre-Tax Income	0,0.00
Income Taxes	0,0.00
Minority Interest	0,0.00
Net Income From Continuing Operations	0,0.00
Net Income From Discontinued Operations	0,0.00
Net Income From Total Operations	0,0.00
Extraordinary Income/Losses	0,0.00
Income From Cum. Effect Of Acct. Change	0,0.00
Income From Tax Loss Carryforward	0,0.00
Other Gains / Losses	0,0.00
Total Net Income	0,0.00
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Preferred Dividends	0,0.00
Net Income Available To Common	0,0.00
Basic EPS From Continuing Ops.	0,0.00
Basic EPS From Discontinued Ops.	0,0.00
Basic EPS From Total Operations	0,0.00
Basic EPS From Extraordinary Inc.	0,0.00
Basic EPS From Cum Effect Of Accounting Change	0,0.00
Basic EPS From Tax Loss Carryf'd.	0,0.00
Basic EPS From Other Gains (Losses)	0,0.00
Basic EPS, Total	0,0.00
Basic Normalized Net Income/Share	0,0.00
EPS From Continuing Ops.	0,0.00
EPS From Discontinued Ops	0,0.00
EPS From Total Ops.	0,0.00
EPS From Extraord. Inc.	0,0.00
EPS From Cum Effect of Accounting Change	0,0.00
EPS From Tax Loss Carfd.	0,0.00
EPS From Other Gains (L)	0,0.00
EPS, Total	0,0.00
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Dividends Paid Per Share	0,0.00

Select Period

CASH FROM OPERATIONS	CASH FROM INVESTING ACTIVITIES	CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

	M Y
Cash Flow From Operating Activities
Net Income (Loss)	0,0.00
Operating Gains/Losses	0,0.00
Gross Operating Profit	0,0.00
(Increase) Decrease In Receivables	0,0.00
(Increase) Decrease In Inventories	0,0.00
(Increase) Decrease In Other Current Assets	0,0.00
(Decrease) Increase In Other Current Liabilities	0,0.00
(Increase) Decrease In Other Working Capital	0,0.00
Other Non-Cash Items	0,0.00
Net Cash From Continuing Operations	0,0.00
Net Cash From Discontinued Operations	0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities	0,0.00
Sale Of Property, Plant & Equipment	0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments	0,0.00
Purchases Of Property, Plant & Equipment	0,0.00
Acquisitions	0,0.00
Purchases Of Short-Term Investments	0,0.00
Other Cash From Investing Activities	0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities	0,0.00
Issuance Of Debt	0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock	0,0.00
Repayment Of Long-Term Debt	0,0.00
Repurchase Of Capital Stock	0,0.00
Payment Of Cash Dividends	0,0.00
Other Financing Charges, Net	0,0.00
Net Cash From Financing Activities	0,0.00
Effect Of Exchange Rate Changes	0,0.00
Net Change In Cash & Cash Equivalents	0,0.00

Earnings Estimates

as of 11:40 ET AM 09/24/2021

	Current Qtr (12/1969)	Next Qtr (12/1969)
Consensus Estimate	n/a	n/a
# of Estimates	n/a	n/a
High Estimate	n/a	n/a
Low Estimate	n/a	n/a
Year Ago EPS	n/a	n/a
Year Over Year Growth Estimate	n/a	n/a

	Current Yr (12/1969)	Next Yr (12/1969)
Consensus Estimate	n/a	n/a
# of Estimates	n/a	n/a
High Estimate	n/a	n/a
Low Estimate	n/a	n/a
Year Ago EPS	n/a	n/a
Year Over Year Growth Estimate	n/a	n/a

	Current Qtr (12/1969)	Next Qtr (12/1969)	Current Year (12/1969)	Next Year (12/1969)
Consensus Estimate	n/a	n/a	n/a	n/a
# of Estimates	n/a	n/a	n/a	n/a
High Estimate	n/a	n/a	n/a	n/a
Low Estimate	n/a	n/a	n/a	n/a
Year Ago EPS	n/a	n/a	n/a	n/a
Year Over Year Growth Estimate	n/a	n/a	n/a	n/a

Insider Information Summary

as of n/a

	% Insiders - n/a
	% Remaining Total Shares - n/a

	Current	1 Month
Net Insider Transaction	n/a	n/a
Shares Bought	n/a	n/a
Shares Sold	n/a	n/a

Insider Activity

Purchases

Sales

Options Exercised

Options Awarded

Transaction Date	Insider/Title	Transaction Type	Market Value	Shares	Average Price	Current Holdings

Learn to Trade Like a Pro

Master The Market with the Help of Our Financial Experts

SUBSCRIBE NOW

STOCKS

By Seeking Alpha

Nov 9, 2010 7:22 PM EST

Latest News

Jun 24, 2010 7:01 AM EDT

May 10, 2010 8:12 PM EDT

Mar 24, 2010 9:35 AM EDT

Mar 8, 2010 11:59 AM EST

Mar 3, 2010 11:54 AM EST

Jan 25, 2010 12:04 PM EST

Jan 25, 2010 7:24 AM EST

Neurocrine Licenses Drug to Abbott:BioBuzz

Jan 25, 2010 6:14 AM EST

Jan 22, 2010 3:16 PM EST

Jan 8, 2010 7:00 AM EST

Nov 23, 2009 1:25 PM EST

Vertex Cures Hard-to-Treat Hep C Patients

Nov 23, 2009 12:59 PM EST

Nov 20, 2009 6:01 AM EST

Nov 18, 2009 8:57 AM EST

Lilly Sinks as Cholesterol-Lowering Pill Trial Shut Down

Nov 16, 2009 11:59 AM EST

Pfizer to Buy King Pharma for $3.6B Cash

Nov 16, 2009 10:51 AM EST

Nov 16, 2009 9:23 AM EST

Merck to Trim Staff as Profit Meets Views

Nov 16, 2009 8:01 AM EST

Nov 6, 2009 7:00 AM EST

Nov 2, 2009 7:12 AM EST

Oct 23, 2009 6:00 AM EDT

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC

Aug 3, 2009 8:57 AM EDT

Jun 18, 2009 3:34 PM EDT

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

Jun 16, 2009 10:55 AM EDT

Recent Articles from TheStreet

Wall Street Preview: Dollar, Oil and Tech in Focus

STOCKS

Stocks reach record highs as earnings season goes into high gear while Tesla passes $1 trillion valuation.

INVESTING

Shares of Twitter edged lower after a Bank of America analyst cut his price target on the stock to $82 from $90.

INVESTING

General Electric is set to report earnings on Tuesday before the open. Will the results be enough to trigger a breakout in GE stock?

MARKETS

Tesla joined an elite club of five U.S. companies with a trillion dollar market value after a $4.4 billion deal with Hertz pushed its shares to a fresh record high of just under $1,000.